Richmond Pharmacology enhances its established GE MUSE platform with the State-of-the-art Mortara 12-lead telemetry setup

Posted:
8
November 2011

Richmond Pharmacology enhances its established GE MUSE platform with theState-of-the-art Mortara 12-lead telemetry setupEnhancing our well tested GE MUSE platform, Richmond Pharmacology today added the state-of-the-art Mortara 12-lead telemetry setup providing the most comprehensive TQT measurement platform available.Key features include:

  • 12-lead Telemetry Monitoring

With the Mortara X12+  and T12S  transmitters, the Surveyor  Telemetry Central System enables continuous 12-lead monitoring and trending for thorough evaluation of ECG intervals, ST segment change, and arrhythmias using VERITAS  ECG algorithms.

  • 12-lead ECG On-Demand

Continuous 12-lead monitoring enables diagnostic 12-lead ECG acquisition on-demand without any additional device or patient hookup.  12-lead ECGs with VERITAS measurements and interpretation can be printed and exported to an E-Scribe� data management system either manually or automatically.This is an alternative to our established GE GETEMED 12-lead Holter platform.At Richmond Pharmacology we are so confident that we can deliver a successful TQT study we ensure a fixed price guarantee. Furthermore our confidence in our experience means that should we fail to show Thorough QT assay sensitivity we will repeat your study at no cost to you.Contact a member of our Business Development team now to discuss your prospective QT study requirements.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more